Greg Walker
Analyst · CJS Securities
Thank you, John. As you may have seen in our earnings release, we have posted in the Investor Relations section of our website, a management report with detailed comments regarding the financial results of PDF for the quarter. Given that, I'm going to focus my verbal comments for the quarter and a few key highlights reflected in those results. Looking at revenue first, as you are aware, the company has adopted ASC 606 or Topic 606 methodology for all revenue reporting, beginning with Q1 in 2018. The company has elected to implement this change using the modified retrospective method. There is a summary of the adjustments related to this change, which is published as part of our Q1 2018 management report, available in the Investor Relations section of our website. Additionally, a detailed description of all the adjustments, impacts and methodology changes related to ASC 606 will be included with our upcoming 10-Q filing. At the summary level, the major adjustments for Q1 are as follows: for opening balances, there was a $5.7 million increase to opening retained earnings, which includes revenue adjustments plus deferred commission expense changes; there is a $1.3 million adjustment to deferred tax liabilities related to the increased opening balance for retained earnings; and then finally, for Q1 activity, the net effect on revenues and costs for Q1 was immaterial and essentially zero. For the remainder of the year, we expect the impact of the new accounting rules to be a reduction of our total revenues for the year of approximately $2 million to $3 million. Now looking at the Q1 results in summary. Total revenues at $24.7 million for the quarter were down $2 million as compared to Q4 2017. Solutions revenues at $18.2 million decreased by $800,000 when compared to Q4 2017, while gainshare revenues at $6.5 million decreased by $1.2 million. The Q1 over Q4 decrease in solutions revenue was primarily the result of higher perpetual software license revenue and related hardware revenues recognized during Q4, which did not reoccur in Q1. The decrease in gainshare revenue was primarily due to 28-nanometer volumes in revenues across multiple customers, partially being offset by an increase in 14-nanometer revenues. Expenses on a GAAP basis, total expenses for the quarter were $25.2 million, approximately $700,000 lower than the previous quarter. This decrease in expense was primarily due to lower variable compensation expenses, lower third-party development cost and the next generation eProbe tool, lower cost to sales related to hardware sold to a customer as part of a software sale in Q4 and lower stock compensation expenses. This decrease in spending was partially offset by severance payments incurred during the quarter related to some of our cost-reduction initiatives begun during the quarter and higher legal expenses and audit fees. On a non-GAAP basis, total expenses for the quarter were $21.8 million, approximately $800,000 lower than the previous quarter. This decrease was primarily due to the items previously mentioned for the decrease in GAAP spending, except for the impact of the severance payments and lower stock compensation expenses, which have been excluded from non-GAAP expenses. Once again, on a GAAP basis, cost to sales was $11.5 million, which was approximately $800,000 lower than the previous quarter. This was primarily due to lower hardware cost mentioned earlier, lower compensation expenses due to reductions in force, lower travel expenses and lower stock compensation expenses, partially offset by the severance expense and payments that I mentioned. On a non-GAAP basis, cost to sales was $10.1 million, approximately $900,000 lower than in Q4. And this was primarily due to items previously mentioned for lower GAAP cost of sales, once again, excluding the impact of stock compensation expense in the severance payments. GAAP R&D expenses were $7.2 million, approximately $400,000 lower than the previous quarter, once again, due to lower third-party development cost on the next generation eProbe tool. Non-GAAP R&D expenses were $6.3 million, approximately $400,000 lower than Q4, again, due to the lower third-party costs. GAAP and non-GAAP SG&A expenses were $6.4 million and $5.4 million, respectively, each increasing approximately $500,000 from the previous quarter, primarily due to higher audit cost involved with the 606 implementation and legal fees. Other expense was approximately $400,000 higher than Q4, primarily due to the impact of a weaker U.S. dollar with respect to our foreign currency denominated expenses. GAAP net loss for the quarter was approximately $400,000, an improvement of $2.2 million over Q4. Non-GAAP net income for the quarter was $2.2 million, down $1.9 million from Q4. Refer to our call transcript from Q4 2017 for an explanation of the impact of the 2017 tax at -- on our Q4 GAAP net loss results. Turning to the balance sheet. Total cash at $98.4 million declined by $2.7 million during the quarter. This reduction was primarily the result of stock repurchases, totaling $4.1 million. The purchase of company stock related to the settlement of employee tax obligations and RSU grant of $600,000. And PP&E expenses related to purchases relating to our -- development of our DFI solution, of $2.4 million. These uses of cash were partially offset by the cash generated from operations of $3.3 million and stock option exercises and ESPP purchases of $1 million. Accounts receivable at approximately $66.2 million at the end of the quarter consisted of $35.4 million of trade accounts receivable and $30.8 million of unbilled accounts receivable. The combined AR was approximately the same as the previous quarter. Additionally, under ASC 606, $3.7 million has been reclassified from unbilled accounts receivable to contract assets and recorded as other current assets. DFO for the combined accounts receivable, increased from 225 days in Q4 to 243 days. DSO, including contract assets, is now 257 days. Of the $30.8 million unbilled AR balance, we expect to build $23.1 million over the next 12 months, of which, $12.2 million will be billed during Q2. During Q1, we collected $25.2 million, which was up from $22.3 million collected in Q4. Since the end of Q1, we have collected $11.11 million of the $35.4 million trade accounts receivable outstanding, which if they had been collected by the end of the quarter, would have reduced our DSO by approximately 40 days. Looking at taxes, our GAAP tax benefit for the quarter was $381,000. This provision consisted of the gross GAAP tax rate of approximately 23.7%, plus adjustments for discrete items of about $190,000. We expect our full year net GAAP and non-GAAP tax provision rate, after discrete items, to be approximately 18.5%, which is in line with our previous outlook. Looking at the remainder of the year, given the market conditions that John has described, we now expect 2018 revenue, excluding ASC 606 impacts, to be approximately flat when compared to 2017. Looking at the impact on revenue of ASC 606, we expect total revenues for the year to be reduced by approximately $2 million to $3 million. As John stated, we expect Q2 revenues to be more heavily affected by the current market conditions in either Q3 or Q4. During Q1, we began implementation of our cost-reduction initiatives and reducing the company's total non-GAAP expenses. These cost reductions will allow the company to make some strategic investments, while still reducing our total non-GAAP spending by approximately 5% or more year-over-year. Given the uncertain market conditions, our goal is to deliver improved non-GAAP earnings as compared to 2017 excluding the impact of ASC 606. With that, I will turn the call over to the operator for Q&A.